Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous ConditionAccesswire • Thursday
Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual MeetingGlobeNewsWire • 04/30/24
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)GlobeNewsWire • 04/26/24
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain CancersAccesswire • 03/28/24
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D UpdateGlobeNewsWire • 02/23/24
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma PatientsGlobeNewsWire • 02/08/24
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024GlobeNewsWire • 01/22/24
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment OptionGlobeNewsWire • 12/21/23
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 DiabetesGlobeNewsWire • 11/27/23
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent GlioblastomaGlobeNewsWire • 10/03/23
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)GlobeNewsWire • 09/21/23
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)GlobeNewsWire • 07/10/23
Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)GlobeNewsWire • 07/06/23